Jardiance and Metformin Interaction: What Clinicians and Patients Need to Know

Do Jardiance and Metformin Interact Pharmacokinetically?

No clinically significant pharmacokinetic interaction exists between empagliflozin and metformin. The two drugs do not share CYP450 metabolic pathways, and neither substantially inhibits or induces the other's elimination. This is confirmed in the FDA-approved label for Synjardy, the fixed-dose combination product containing both agents.

Metabolism and Elimination Pathways

Empagliflozin is metabolized primarily via glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9. It is not a substrate, inhibitor, or inducer of CYP3A4, CYP2C8, or P-glycoprotein at clinically relevant concentrations. Approximately 41% of an oral dose is recovered in urine and 51% in feces, largely as glucuronide conjugates. [1]

Metformin undergoes no hepatic metabolism at all. It is excreted unchanged by the kidneys via active tubular secretion, primarily through organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins MATE1 and MATE2-K. Plasma half-life is roughly 6.5 hours; renal clearance substantially exceeds glomerular filtration rate, confirming active secretion. [2]

Because their elimination routes are entirely separate, co-administration does not alter the AUC or Cmax of either drug in a clinically meaningful way.

What the FDA Label Confirms

The Synjardy prescribing information states: "No dose adjustment is recommended for either empagliflozin or metformin based on drug-drug interaction studies." [1] A dedicated two-way crossover pharmacokinetic study in healthy volunteers showed that the geometric mean ratios for empagliflozin AUC and Cmax remained within the standard 80 to 125% bioequivalence boundaries when co-administered with metformin 1,000 mg.

The Real Concern: Pharmacodynamic Overlap and Renal Function

While the PK story is clean, both drugs share a critical pharmacodynamic dependency on intact kidney function. This is where the interaction becomes clinically meaningful.

Metformin and Lactic Acidosis

Metformin accumulates when renal clearance falls. Elevated plasma metformin inhibits mitochondrial complex I in hepatocytes, reducing pyruvate oxidation and increasing conversion of lactate to pyruvate. The result is metformin-associated lactic acidosis (MALA), a rare but life-threatening complication.

Reported incidence is approximately 3 to 5 cases per 100,000 patient-years, with case-fatality rates historically cited between 25 to 50% in older series, though more recent data suggest mortality closer to 25% when patients are managed in a contemporary ICU setting. [3]

The FDA revised metformin's label in 2016 to replace the absolute serum-creatinine contraindication with an eGFR-based framework:

• eGFR <45 mL/min/1.73 m²: Do not initiate metformin; consider discontinuing in existing users.
• eGFR <30 mL/min/1.73 m²: Contraindicated; discontinue.

This means a patient on stable metformin whose eGFR drifts from 52 to 43 while on empagliflozin has crossed a threshold requiring active clinical decision-making, not just passive observation.

Empagliflozin and Renal-Dependent Glycemic Efficacy

Empagliflozin blocks SGLT2 in the proximal tubule, reducing renal glucose reabsorption by approximately 70 to 90 g per day in patients with normal renal function. That capacity shrinks as nephron mass falls.

In the EMPA-REG OUTCOME trial (N=7,020 patients with type 2 diabetes and established cardiovascular disease), the mean eGFR at baseline was 74 mL/min/1.73 m². Empagliflozin 10 mg and 25 mg produced HbA1c reductions of 0.54% and 0.60% respectively vs. Placebo at 206 weeks. The cardiovascular benefit (14% relative risk reduction in 3-point MACE, P<0.001) was observed regardless of baseline eGFR stratum down to 30 mL/min/1.73 m², and the cardiorenal benefit is now considered largely independent of glycemic action. [4]

Current prescribing guidance reflects this dual story:

• eGFR <45: Do not initiate empagliflozin for glycemic control; cardiorenal indications may still apply.
• eGFR <20 (or dialysis): Empagliflozin is not recommended.

The 2024 American Diabetes Association Standards of Care specify that SGLT2 inhibitors with proven cardiovascular or kidney benefit should be continued even as eGFR declines, down to approximately 20 to 25 mL/min/1.73 m², to preserve their organ-protective effects. [5]

The Combined Picture

A patient taking both drugs has two overlapping eGFR thresholds converging from different directions. Empagliflozin may be safe to continue (for cardiorenal benefit) at eGFRs where metformin must be stopped (eGFR <30 to 45). Failing to recognize this creates a window where the clinician continues both drugs on the assumption that "they go together," while the patient's metformin is accumulating to dangerous levels.

Monitoring Requirements for the Combination

Baseline Assessment Before Starting Either Drug

Before prescribing empagliflozin and metformin together, obtain:

1. Serum creatinine and estimated eGFR (CKD-EPI 2021 equation preferred).
2. Urinalysis with urine albumin-to-creatinine ratio (UACR), both to stage kidney disease and because albuminuria is an independent indication modifier for SGLT2 inhibitors.
3. Hepatic function panel, liver disease raises lactate production and increases MALA risk with metformin.
4. Volume status assessment, empagliflozin's osmotic diuresis can exacerbate pre-existing volume depletion, which in turn reduces renal perfusion and elevates metformin exposure.

Ongoing Renal Monitoring Schedule

The FDA label for Synjardy recommends assessing renal function before initiating treatment and periodically thereafter. [1] In clinical practice, the following schedule aligns with ADA and KDIGO 2022 guidelines:

• eGFR 60 to 90: Annual creatinine/eGFR.
• eGFR 45 to 59: Every 6 months.
• eGFR 30 to 44: Every 3 months; consider discontinuing metformin and evaluating whether empagliflozin's cardiorenal benefit justifies continuation.
• eGFR <30: Stop metformin; reassess empagliflozin indication.

Iodinated Contrast Procedures

Patients receiving iodinated contrast agents face transient renal hypoperfusion. The FDA recommends holding metformin at the time of, or prior to, iodinated contrast administration in patients with eGFR <60 mL/min/1.73 m², hepatic impairment, or hemodynamic instability, and re-evaluating renal function 48 hours after the procedure before resuming. [2] Empagliflozin does not require the same protocol, but any significant post-contrast acute kidney injury would independently trigger re-assessment of both drugs.

Signs and Symptoms to Counsel Patients On

Clinicians should explicitly counsel patients on:

• Lactic acidosis warning signs: Unexplained myalgia, respiratory distress, abdominal pain, hypothermia, or hypotension, seek emergency care immediately.
• Volume depletion signs: Lightheadedness, dizziness on standing, decreased urine output, these may reflect empagliflozin-mediated diuresis or dehydration from illness.
• Sick-day rules: Hold both metformin and empagliflozin during acute illness, prolonged fasting, or situations likely to cause dehydration (vomiting, diarrhea, high fever). Resume only after adequate oral intake and confirmed hemodynamic stability.

The ADA 2024 Standards of Care state: "Metformin should be withheld during times of restricted food and fluid intake or periods that may cause dehydration." [5]

Glycemic Effects of the Combination

Additive but Mechanistically Independent HbA1c Lowering

Empagliflozin lowers blood glucose by increasing urinary glucose excretion independent of insulin. Metformin lowers glucose primarily by suppressing hepatic gluconeogenesis and, to a lesser degree, by improving peripheral insulin sensitivity. Because their mechanisms do not overlap, the HbA1c-lowering effect is additive.

In a 24-week randomized trial of empagliflozin added to metformin (N=637), empagliflozin 10 mg reduced HbA1c by 0.57% and empagliflozin 25 mg by 0.64% relative to placebo, on a metformin background. Fasting plasma glucose fell by approximately 18 mg/dL and 21 mg/dL in the 10 mg and 25 mg groups, respectively. [6]

Hypoglycemia Risk Is Low

Neither drug stimulates insulin secretion. The combination does not carry an intrinsic hypoglycemia risk beyond each agent's individual profile, which is minimal. This contrasts sharply with sulfonylureas or insulin added to either backbone.

Hypoglycemia rates in empagliflozin-plus-metformin arms of clinical trials are generally below 1 to 2%, and most episodes are mild. If a sulfonylurea or insulin is added to this combination, the sulfonylurea or insulin dose typically warrants reduction.

Weight and Blood Pressure Effects

The combination produces complementary metabolic benefits. Metformin is weight-neutral to modestly weight-reducing. Empagliflozin produces mean body weight reductions of 2 to 3 kg at standard doses, primarily from glycosuria-related caloric loss and osmotic diuresis. [4]

Empagliflozin also consistently reduces systolic blood pressure by 3 to 5 mmHg in clinical trials, an effect attributed to natriuresis and plasma volume reduction. Metformin has no meaningful direct antihypertensive effect. The blood pressure reduction from empagliflozin may be clinically useful in type 2 diabetes patients with hypertension but requires monitoring in patients on antihypertensives to avoid hypotension.

Fixed-Dose Combination: Synjardy

Boehringer Ingelheim and Eli Lilly's Synjardy tablet combines empagliflozin and metformin HCl in four dose configurations:

• 5 mg empagliflozin / 500 mg metformin
• 5 mg empagliflozin / 1,000 mg metformin
• 12.5 mg empagliflozin / 500 mg metformin
• 12.5 mg empagliflozin / 1,000 mg metformin

Synjardy XR (extended-release metformin) is also available for patients who experience gastrointestinal intolerance with immediate-release formulations. Taking metformin with food reduces GI side effects substantially, and this applies equally to the fixed-dose tablet. [1]

The FDA approved Synjardy in August 2015. Using a fixed-dose combination reduces pill burden and may improve adherence, though it reduces dosing flexibility. Patients who need the cardiorenal-protective dose of empagliflozin (10 mg, not 5 mg) may be better served by separate tablets unless dose titration is complete.

Special Populations

Patients with Heart Failure

EMPA-REG OUTCOME demonstrated a 35% relative risk reduction in hospitalization for heart failure with empagliflozin. [4] The EMPEROR-Reduced trial (N=3,730) further confirmed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% vs. Placebo in patients with HFrEF (ejection fraction <40%), with benefit seen regardless of diabetes status. [7]

In heart failure, metformin had historically been avoided due to concerns about reduced renal and hepatic perfusion. The 2022 AHA/ACC Heart Failure Guideline states that metformin "can be used" in stable heart failure patients with eGFR above 30 mL/min/1.73 m², noting that the older absolute contraindication was based on theoretical concerns rather than clinical outcome data. [8] Still, close renal monitoring remains prudent in this population.

Older Adults

Age-related decline in GFR means older patients on this combination require more frequent monitoring. The UKPDS 34 trial established metformin's long-term safety and benefit in overweight type 2 diabetes patients, but enrolled a younger population. In patients above age 75, any acute illness, hospitalization, or contrast procedure should prompt automatic reassessment of metformin appropriateness.

Patients with CKD and Albuminuria

CREDENCE (N=4,401) showed canagliflozin (a related SGLT2 inhibitor) reduced the primary composite kidney outcome by 30% vs. Placebo in patients with type 2 diabetes and CKD. The EMPA-KIDNEY trial (N=6,609) extended this to empagliflozin specifically, showing a 28% relative risk reduction in kidney disease progression or cardiovascular death vs. Placebo across a broad CKD population with eGFR 20 to 45 or eGFR 45 to 90 with UACR ≥200 mg/g. [9] In these patients, empagliflozin should generally be continued; metformin should be assessed against the eGFR thresholds above.

Dosing Guidance for the Combination

Starting doses and titration for patients who are not already on either drug:

1. Metformin: Begin at 500 mg once daily or 500 mg twice daily with meals to reduce GI side effects. Increase by 500 mg every 1 to 2 weeks to the effective dose, typically 1,000 to 2,000 mg/day. Maximum is 2,550 mg/day, though most glycemic benefit is achieved by 2,000 mg/day.
2. Empagliflozin: Begin at 10 mg once daily in the morning, with or without food. May increase to 25 mg once daily for additional glycemic lowering if tolerated and eGFR remains adequate. For heart failure or CKD indications, 10 mg once daily is the approved and studied dose.
3. Renal check before escalation: Confirm eGFR before increasing either drug's dose, particularly if the patient has had any intercurrent illness since the last measurement.

The prescribing information for empagliflozin notes that no dose adjustment is needed for mild hepatic impairment (Child-Pugh A) but recommends avoiding the drug in severe hepatic impairment (Child-Pugh C) due to limited data. [1] Metformin, with its zero hepatic metabolism, is contraindicated in any significant hepatic impairment because of MALA risk.

Other Drug Interactions to Consider in Patients on Both Agents

Patients with type 2 diabetes typically take multiple medications. While empagliflozin and metformin do not interact with each other, both interact with other drugs in ways that matter when they share the same regimen.

Drugs That Affect Renal Perfusion

NSAIDs, ACE inhibitors, ARBs, and diuretics all reduce renal perfusion to varying degrees. Combining any of these with metformin raises MALA risk. Empagliflozin already produces modest diuresis; adding a loop diuretic increases the risk of volume depletion and acute kidney injury. Monitoring of electrolytes and creatinine becomes more important in this scenario.

Carbonic Anhydrase Inhibitors

Topiramate and zonisamide inhibit carbonic anhydrase and can cause a non-anion-gap metabolic acidosis, reducing bicarbonate buffering capacity. This may worsen lactic acidosis risk if metformin levels rise, though the interaction is theoretical and no large outcome data exist.

Alcohol

Heavy alcohol use impairs hepatic lactate clearance and can cause hypoglycemia in combination with metformin. Patients should be counseled to limit alcohol, particularly on an empty stomach or during illness.